Evidence map›Paper›PMID 35790660›Full record

ArticleEndocrine2022

Hyperglycemia is associated with adverse prognosis in patients with pancreatic neuroendocrine neoplasms.

Pin Zhang, Zhiwen Xiao, Huaxiang Xu, Xinzhe Zhu, Lei Wang, Dan Huang, Yun Liang, Quanxing Ni, Jie Chen, Xianjun Yu and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Endocrine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Metabolic changes in neuroendocrine neoplasms.Cellular and molecular life sciences : CMLS · 2025
    Review
  4. Observational
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Pin Zhang *Center for Neuroendocrine Tumors, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Zhiwen Xiao *Center for Neuroendocrine Tumors, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Huaxiang Xu *Center for Neuroendocrine Tumors, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Xinzhe ZhuCenter for Neuroendocrine Tumors, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Lei WangDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Dan HuangDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Yun LiangCenter for Neuroendocrine Tumors, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Quanxing NiCenter for Neuroendocrine Tumors, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Jie ChenCenter for Neuroendocrine Tumors, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Xianjun YuCenter for Neuroendocrine Tumors, Fudan University Shanghai Cancer Center, Shanghai, 200032, China. yuxianjun@fudanpci.org.
Guopei LuoCenter for Neuroendocrine Tumors, Fudan University Shanghai Cancer Center, Shanghai, 200032, China. luoguopei@fudnapci.org.ORCID http://orcid.org/0000-0002-6582-9624
Shanghai Medical College of Fudan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough glucose has a well-recognized protumoral role and the pancreas is a critical organ in adjusting glucose metabolism, the clinical value of hyperglycemia in pancreatic neuroendocrine neoplasms (pNENs) remains largely unidentified.

methodsA retrospective study including 335 patients with pathologically confirmed pNENs was conducted. A baseline fasting blood glucose concentration ≥5.6 mmol/L was defined as hyperglycemia (otherwise, normal). Survival and regression analyses were performed.

resultsCompared with patients with normal glucose, patients with hyperglycemia (47.8%) had a higher proportion of preexisting diabetes mellitus (DM) (36.9% vs. 4.6%, p < 0.001), lymph node involvement (31.0% vs. 14.6%, p = 0.002), distant metastasis (34.4% vs. 22.9%, p = 0.019), and carbohydrate antigen 19-9 (CA19-9) ≥ 37 U/mL (16.6% vs. 7.2%, p = 0.009). Hyperglycemia was associated with CA19-9 ≥ 37 U/mL (Odds Ratio (OR) = 3.19, 95% CI: 1.11-9.17, p = 0.031), lymph node involvement (OR = 2.32, 95% CI: 1.02-5.28, p = 0.045), nonfunctional tumors (OR = 9.90, 95% CI: 2.11-46.34, p = 0.004), and preexisting diabetes (OR = 18.24, 95% CI: 4.06-81.95, p < 0.001). Hyperglycemia was an independent determinant for overall survival in the multivariate analysis (hazard ratio (HR) = 2.65, 95% CI: 1.31-5.34, p = 0.006).

conclusionHyperglycemia is an independent predictor of overall survival and is associated with preexisting DM or lymphatic metastasis in patients with pNENs. Patients with hyperglycemia and resectable pNENs may benefit from radical resection with dissection of regional lymph nodes.

Indexed as

HyperglycemiaNeuroendocrine TumorsPancreatic NeoplasmsCA-19-9 AntigenGlucoseHumansLymph NodesNeoplasm StagingPrognosisRetrospective StudiesCA-19-9 AntigenGlucoseCA19-9Diabetes mellitusImpaired glucose toleranceLymph node metastasisPancreatic neuroendocrine tumorPrediabetes

Identifiers

PMID35790660
OpenAlexW4284680700

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.